{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T23:01:30Z","timestamp":1773270090439,"version":"3.50.1"},"reference-count":49,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.3892\/ijmm.2016.2560","type":"journal-article","created":{"date-parts":[[2016,4,12]],"date-time":"2016-04-12T07:11:57Z","timestamp":1460445117000},"page":"1457-1464","source":"Crossref","is-referenced-by-count":10,"title":["Anti-inflammatory effects of novel AP-1 and NF-\u03baB inhibitors in dextran-sulfate-sodium-induced colitis in rats"],"prefix":"10.3892","volume":"37","author":[{"given":"MAGDY","family":"EL-SALHY","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KAZUO","family":"UMEZAWA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2016,4,12]]},"reference":[{"key":"key20180107234655_b1-ijmm-37-06-1457","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1177\/1756283X12473675","article-title":"Glucocorticosteroids in the treatment of inflammatory bowel disease and approaches to minimizing systemic activity","volume":"6","author":"Prantera","year":"2013","journal-title":"Therap Adv Gastroenterol"},{"key":"key20180107234655_b2-ijmm-37-06-1457","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1053\/j.gastro.2011.01.055","article-title":"Epidemiology and natural history of inflammatory bowel diseases","volume":"140","author":"Cosnes","year":"2011","journal-title":"Gastroenterology"},{"issue":"Suppl 5","key":"key20180107234655_b3-ijmm-37-06-1457","doi-asserted-by":"crossref","first-page":"V1","DOI":"10.1136\/gut.2004.043372","article-title":"IBD Section, British Society of Gastroenterology: Guidelines for the management of inflammatory bowel disease in adults","volume":"53","author":"Carter","year":"2004","journal-title":"Gut"},{"key":"key20180107234655_b4-ijmm-37-06-1457","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMra020831","article-title":"Inflammatory bowel disease","volume":"347","author":"Podolsky","year":"2002","journal-title":"N Engl J Med"},{"key":"key20180107234655_b5-ijmm-37-06-1457","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1053\/bega.2002.0354","article-title":"The current future understanding of inflammatory bowel disease","volume":"16","author":"Podolsky","year":"2002","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"key20180107234655_b6-ijmm-37-06-1457","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1053\/j.gastro.2004.01.063","article-title":"Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences","volume":"126","author":"Loftus","year":"2004","journal-title":"Gastroenterology"},{"key":"key20180107234655_b7-ijmm-37-06-1457","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0889-8553(01)00002-4","article-title":"Epidemiology of inflammatory bowel disease","volume":"31","author":"Loftus","year":"2002","journal-title":"Gastroenterol Clin North Am"},{"key":"key20180107234655_b8-ijmm-37-06-1457","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1097\/MIB.0b013e318281334d","article-title":"Inflammatory bowel disease prevalence by age, gender, race, and geographic location in the U.S. military health care population","volume":"19","author":"Betteridge","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"key20180107234655_b9-ijmm-37-06-1457","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/00054725-200108000-00013","article-title":"Epidemiology of inflammatory bowel disease in Asia","volume":"7","author":"Yang","year":"2001","journal-title":"Inflamm Bowel Dis"},{"key":"key20180107234655_b10-ijmm-37-06-1457","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1751-2980.2008.00355.x","article-title":"Inflammatory bowel disease: A survey of the epidemiology in Asia","volume":"10","author":"Goh","year":"2009","journal-title":"J Dig Dis"},{"key":"key20180107234655_b11-ijmm-37-06-1457","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.suc.2006.05.009","article-title":"New therapies for the treatment of inflammatory bowel disease","volume":"86","author":"Sands","year":"2006","journal-title":"Surg Clin North Am"},{"issue":"Suppl 3","key":"key20180107234655_b12-ijmm-37-06-1457","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000342731","article-title":"The risks and benefits of early immunosuppression and biological therapy","volume":"30","author":"Sands","year":"2012","journal-title":"Dig Dis"},{"key":"key20180107234655_b13-ijmm-37-06-1457","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0016-5085(92)90822-G","article-title":"Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease","volume":"103","author":"Prantera","year":"1992","journal-title":"Gastroenterology"},{"key":"key20180107234655_b14-ijmm-37-06-1457","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1097\/MIB.0b013e31828132cb","article-title":"Adherence to anti-TNF therapy in inflammatory bowel diseases: A systematic review","volume":"19","author":"Lopez","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"key20180107234655_b15-ijmm-37-06-1457","doi-asserted-by":"crossref","first-page":"136","DOI":"10.2174\/138945010790309911","article-title":"Anti TNF-alpha treatment for Crohn' disease: 'm\u00e9nage a trois'","volume":"11","author":"Danese","year":"2010","journal-title":"Curr Drug Targets"},{"issue":"Suppl 3","key":"key20180107234655_b16-ijmm-37-06-1457","doi-asserted-by":"crossref","first-page":"S217","DOI":"10.1016\/S0399-8320(09)73157-4","article-title":"New and emerging biologics in the treatment of inflammatory bowel disease: Quo vadis?","volume":"33","author":"Danese","year":"2009","journal-title":"Gastroenterol Clin Biol"},{"key":"key20180107234655_b17-ijmm-37-06-1457","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/med.20103","article-title":"Biological agents for ulcerative colitis: Hypes and hopes","volume":"28","author":"Danese","year":"2008","journal-title":"Med Res Rev"},{"key":"key20180107234655_b18-ijmm-37-06-1457","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/apt.12284","article-title":"Review article: The role of anti-TNF in the management of ulcerative colitis - past, present and future","volume":"37","author":"Danese","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"key20180107234655_b19-ijmm-37-06-1457","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/j.1365-2036.2011.04598.x","article-title":"Review article: Infliximab for Crohn's disease treatment - shifting therapeutic strategies after 10 years of clinical experience","volume":"33","author":"Danese","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"key20180107234655_b20-ijmm-37-06-1457","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2174\/138955706777698624","article-title":"Biological therapies for inflammatory bowel disease: Research drives clinics","volume":"6","author":"Danese","year":"2006","journal-title":"Mini Rev Med Chem"},{"key":"key20180107234655_b21-ijmm-37-06-1457","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.bmcl.2011.11.045","article-title":"Synthesis and biological evaluation of molecular probes based on the 9-methylstreptimidone derivative DTCM-glutarimide","volume":"22","author":"Ota","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"key":"key20180107234655_b22-ijmm-37-06-1457","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1097\/TP.0b013e31827b3d90","article-title":"Immunosuppressive effects of DTCM-G, a novel inhibitor of the mTOR downstream signaling pathway","volume":"95","author":"Shibasaki","year":"2013","journal-title":"Transplantation"},{"key":"key20180107234655_b23-ijmm-37-06-1457","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.crohns.2011.08.011","article-title":"A novel NF-\u03baB inhibitor, dehydroxymethylepoxyquinomicin, ameliorates inflammatory colonic injury in mice","volume":"6","author":"Funakoshi","year":"2012","journal-title":"J Crohn's Colitis"},{"key":"key20180107234655_b24-ijmm-37-06-1457","doi-asserted-by":"crossref","first-page":"813804","DOI":"10.1155\/2014\/813804","article-title":"Amelioration of severe TNBS induced colitis by novel AP-1 and NF-\u03baB inhibitors in rats","volume":"2014","author":"El-Salhy","year":"2014","journal-title":"ScientificWorldJournal"},{"key":"key20180107234655_b25-ijmm-37-06-1457","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/0016-5085(95)90599-5","article-title":"Experimental models of inflammatory bowel disease","volume":"109","author":"Elson","year":"1995","journal-title":"Gastroenterology"},{"key":"key20180107234655_b26-ijmm-37-06-1457","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S0960-894X(00)00114-1","article-title":"Synthesis of NF-kappaB activation inhibitors derived from epoxyquinomicin C","volume":"10","author":"Matsumoto","year":"2000","journal-title":"Bioorg Med Chem Lett"},{"key":"key20180107234655_b27-ijmm-37-06-1457","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1017\/jns.2012.23","article-title":"A salmon peptide diet alleviates experimental colitis as compared with fish oil","volume":"2","author":"Grimstad","year":"2013","journal-title":"J Nutr Sci"},{"key":"key20180107234655_b28-ijmm-37-06-1457","doi-asserted-by":"crossref","first-page":"G1298","DOI":"10.1152\/ajpgi.2000.279.6.G1298","article-title":"NK-1 antagonist reduces colonic inflammation and oxidative stress in dextran sulfate-induced colitis in rats","volume":"279","author":"Stucchi","year":"2000","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"key20180107234655_b29-ijmm-37-06-1457","first-page":"238","article-title":"Clinicopathologic study of dextran sulfate sodium experimental murine colitis","volume":"69","author":"Cooper","year":"1993","journal-title":"Lab Invest"},{"key":"key20180107234655_b30-ijmm-37-06-1457","doi-asserted-by":"crossref","first-page":"483578","DOI":"10.1155\/2014\/483578","article-title":"Flt3\/Flt3L participates in the process of regulating dendritic cells and regulatory T cells in DSS-induced colitis","volume":"2014","author":"Mao","year":"2014","journal-title":"Gastroenterol Res Pract"},{"key":"key20180107234655_b31-ijmm-37-06-1457","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1046\/j.1365-2249.1998.00728.x","article-title":"Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines","volume":"114","author":"Dieleman","year":"1998","journal-title":"Clin Exp Immunol"},{"key":"key20180107234655_b32-ijmm-37-06-1457","first-page":"1341","article-title":"Animal models of ulcerative colitis and their application in drug research","volume":"7","author":"Low","year":"2013","journal-title":"Drug Des Devel Ther"},{"key":"key20180107234655_b33-ijmm-37-06-1457","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00011-011-0348-z","article-title":"Inhibition of macrophage activation and suppression of graft rejection by DTCM-glutarimide, a novel piperidine derived from the antibiotic 9-methylstreptimidone","volume":"60","author":"Takeiri","year":"2011","journal-title":"Inflamm Res"},{"key":"key20180107234655_b34-ijmm-37-06-1457","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.biopha.2011.02.003","article-title":"Possible role of peritoneal NF-\u03baB in peripheral inflammation and cancer: Lessons from the inhibitor DHMEQ","volume":"65","author":"Umezawa","year":"2011","journal-title":"Biomed Pharmacother"},{"key":"key20180107234655_b35-ijmm-37-06-1457","doi-asserted-by":"crossref","first-page":"5780","DOI":"10.1021\/jm8006245","article-title":"Inactivation of NF-kappaB components by covalent binding of (\u2212)-dehydroxymethylepoxyquinomicin to specific cysteine residues","volume":"51","author":"Yamamoto","year":"2008","journal-title":"J Med Chem"},{"key":"key20180107234655_b36-ijmm-37-06-1457","doi-asserted-by":"crossref","first-page":"24625","DOI":"10.1074\/jbc.M112063200","article-title":"Inhibition of tumor necrosis factor-alpha-induced nuclear translocation and activation of NF-kappa B by dehydroxymethy-lepoxyquinomicin","volume":"277","author":"Ariga","year":"2002","journal-title":"J Biol Chem"},{"issue":"Suppl 1","key":"key20180107234655_b37-ijmm-37-06-1457","doi-asserted-by":"crossref","first-page":"i109","DOI":"10.1136\/ard.2010.140533","article-title":"Targeting inflammation by modulating the Jun\/AP-1 pathway","volume":"70","author":"Schonthaler","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"key20180107234655_b38-ijmm-37-06-1457","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1084\/jem.193.5.631","article-title":"Essential role of nuclear factor (NF)-kappaB-inducing kinase and inhibitor of kappaB (IkappaB) kinase alpha in NF-kappaB activation through lymphotoxin beta receptor, but not through tumor necrosis factor receptor I","volume":"193","author":"Matsushima","year":"2001","journal-title":"J Exp Med"},{"key":"key20180107234655_b39-ijmm-37-06-1457","first-page":"239","article-title":"Naturally occurring and synthetic inhibitors of NF-kappaB functions","volume":"15","author":"Umezawa","year":"2000","journal-title":"Anticancer Drug Des"},{"key":"key20180107234655_b40-ijmm-37-06-1457","first-page":"593020","article-title":"Inhibition of NF-\u03baB by dehydroxymethylepoxyquinomicin suppresses invasion and synergistically potentiates temozolomide and \u03b3-radiation cytotoxicity in glioblastoma cells","volume":"2013","author":"Brassesco","year":"2013","journal-title":"Chemother Res Pract"},{"key":"key20180107234655_b41-ijmm-37-06-1457","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.canlet.2014.03.030","article-title":"The NF-\u03baB inhibitor DHMEQ decreases survival factors, overcomes the protective activity of microenvironment and synergizes with chemotherapy agents in classical Hodgkin lymphoma","volume":"349","author":"Celegato","year":"2014","journal-title":"Cancer Lett"},{"key":"key20180107234655_b42-ijmm-37-06-1457","first-page":"19","article-title":"Antitumor effect of dehydroxymethylepoxyquinomicin, a small molecule inhibitor of nuclear factor-\u03baB, on glioblastoma","volume":"14","author":"Fukushima","year":"2012","journal-title":"Neurooncol"},{"key":"key20180107234655_b43-ijmm-37-06-1457","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/bjc.2012.321","article-title":"Enhancement of radiosensitivity by a unique novel NF-\u03baB inhibitor, DHMEQ, in prostate cancer","volume":"107","author":"Kozakai","year":"2012","journal-title":"Br J Cancer"},{"key":"key20180107234655_b44-ijmm-37-06-1457","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.canlet.2012.02.008","article-title":"The novel NF-\u03baB inhibitor DHMEQ synergizes with celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism","volume":"322","author":"Lampiasi","year":"2012","journal-title":"Cancer Lett"},{"key":"key20180107234655_b45-ijmm-37-06-1457","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1016\/j.bbamcr.2014.07.010","article-title":"Poly (ADP-ribose) polymerase inhibition synergizes with the NF-\u03baB inhibitor DHMEQ to kill hepatocellular carcinoma cells","volume":"1843","author":"Lampiasi","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"key20180107234655_b46-ijmm-37-06-1457","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.bbrc.2010.11.007","article-title":"Involvement of autocrine CXCL12\/CXCR4 system in the regulation of ovarian carcinoma cell invasion","volume":"403","author":"Miyanishi","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"key20180107234655_b47-ijmm-37-06-1457","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/j.1349-7006.2011.01901.x","article-title":"Inhibition of nuclear factor-kappaB suppresses peritoneal dissemination of gastric cancer by blocking cancer cell adhesion","volume":"102","author":"Mino","year":"2011","journal-title":"Cancer Sci"},{"key":"key20180107234655_b48-ijmm-37-06-1457","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s10585-012-9544-7","article-title":"Combined effect of dehydroxymethylepoxyquinomicin and gemcitabine in a mouse model of liver metastasis of pancreatic cancer","volume":"30","author":"Suzuki","year":"2013","journal-title":"Clin Exp Metastasis"},{"key":"key20180107234655_b49-ijmm-37-06-1457","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.oraloncology.2011.03.001","article-title":"Anti-tumor activity of dehydroxymethylepoxyquinomicin against human oral squamous cell carcinoma cell lines in vitro and in vivo","volume":"47","author":"Yasuda","year":"2011","journal-title":"Oral Oncol"}],"container-title":["International Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ijmm.2016.2560\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,7]],"date-time":"2018-01-07T19:22:40Z","timestamp":1515352960000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ijmm.2016.2560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,12]]},"references-count":49,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2016,4,12]]},"published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.3892\/ijmm.2016.2560"],"URL":"https:\/\/doi.org\/10.3892\/ijmm.2016.2560","relation":{},"ISSN":["1107-3756","1791-244X"],"issn-type":[{"value":"1107-3756","type":"print"},{"value":"1791-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,12]]}}}